A	B	C
1	Main
2		Brand Name	Orencia, fka BMS-188667
3		Generic Name	abatacept
4		Manufacturing	Complex - BMY's first internal biologic
5		Indication	40% of patients fail TNF
6		Administration	IV infusion requires an office visit as opposed to self-administered sc
7		Sales Force	150 reps, 2/3 have TNF selling experience
8		Clinical Studies	p3 AIM (abatacept in Inadequate responders to Methotrexate)
9			Orencia+MTX for two years, 82% achieved ACR20 at year 1 and 80% achieved ACR20 in year 2.
10			54% achieved ACR50 at year 1 and 56% achieved ACR50 responses in year 2.
11			32% achieved ACR70 at year 1 and 34% achieved ACR70 responses in year 2.
12
13			Phase III lupus
14			Failed: 79.7% new flares versus 82.5% in placebo.